You are seeing Ask web results for enzyme glaucoma because there was not a match on Dictionary.com.
|
Even a dose as small as 0.25 ml. of the solution may cause enzyme glaucoma. For that reason the smallest quantity of enzyme should be used for successful zonulysis. Another cause of enzyme glaucoma is that it may be due to oedema of the angle near the incision where the enzyme may exaggerate the oedema of the incision.
|
|
medgadget -- medical technologies weblog ... They combined nanoceria with a compound that blocks activity of an enzyme (hCAII) believed to play a central role in glaucoma. That disease involves abnormally high pressure of the fluid inside the eye, which, if left untreated, can result in damage to the optic nerve and vision loss.
|
||
|
in Primary Open-Angle Glaucoma. Bernard I. Weinsrein, Pedda Munnongi, Gory G. Gordon, and A. Louis Sourhren. Assays of cortisol-metabolizing enzymes in ...
|
||
|
Primary open-angle glaucoma (POAG), the most common form ... CAT and MPO enzyme activities, and MDA levels are given as mean standard deviation. It was evaluated by ANOVA as to whether there was a significant difference in terms of these variables by forming a general linear model by taking age and gender as covariates.
|
||
production of the enzyme glaucoma might be ... in theincidence and severity of the enzyme glaucoma, even 0.25 cc of a-chymotrypsin produced an ...
|
||
|
This information will help in the study of inhibitors that can block the enzyme, which may lead to medicines that have fewer side effects than current drugs being used to treat either Alzheimer's disease or glaucoma.
|
||
|
Angiotensin-Converting Enzyme Insertion-Deletion Polymorphism in Primary Open-Angle Glaucoma; Mehtap Ozkura, brahim Erbagcib, Kivanc Gungorb, Muradiye Nacaka, Sukru Aynaciogluc, Necdet A. Bekirb; Departments of aPharmacology and bOphthalmology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey;
|
||
|
Phase I Investigator for Schering-Plough, Angiotensin Converting Enzyme Anti-Glaucoma Medication ; Phase I Investigator of Insite Vision, Pilosite Study 1992-1993, Betasite, 1994 ; Phase III Sub-investigator for Altana Pharmaceuticals for Ciclesonide, 2003-present ;
|
||
|
an agent that inhibits the enzyme carbonic anhydrase; used in treatment of glaucoma and sometimes for epilepsy, familial periodic paralysis, acute mountain sickness, and kidney stones made of uric acid. ... This information is provided by an independent source. MerckSource is a registered trademark of Merck & Co., Inc.
|
||
|
In order to evaluate further the clinical roles of serum autoantibody against NSE in glaucoma, serum autoantibody against NSE was examined by western blot analysis and enzyme-linked immunosorbent assay (ELISA) in 4 patients with ocular hypertension (OH) and 242 patients with glaucoma (normal tension glaucoma [NTG],
|
